ALTASCIENCES
Altasciences is pleased to support SiteOne Therapeutics with a Phase I, randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. ST-2427 is a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain; by selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system.
Amy Denvir, General Manager of Altasciences’ Kansas City clinical site, says, “We are proud to partner with SiteOne Therapeutics and help move this important therapeutic into clinical trials. Helping bring to market a new approach that may provide a non-opioid option to treat moderate- to-severe pain is an exciting prospect, and we look forward to delivering this ground-breaking research. ”
Click here to read the SiteOne press release .
Altasciences has designed and conducted hundreds of first-in-human trials by offering comprehensive, full service, early development solutions. With a focus on developing sound strategies combined with operational efficiencies, the company minimizes the time taken to make critical go/no-go decisions by harmonizing clinical pharmacology services, biomarker capabilities, PK/PD analysis expertise, and program knowledge.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005827/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic to be Acquired by Blackstone and TPG for up to $79 per Share21.10.2025 14:41:00 CEST | Press release
Hologic Stockholders to Receive $76 per Share in Cash Plus a Contingent Value Right of up to $3 per Share Payable Upon Achieving Certain Revenue MilestonesRepresents 46% Premium to Hologic’s Closing Price on Last Trading Day Prior to Media Reports of Possible TransactionTransaction Includes Significant Minority Investments from ADIA and GICTransaction Will Help Hologic Strengthen its Leadership in Women’s Health and Accelerate Growth Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into a definitive agreement to be acquired by funds managed by Blackstone (“Blackstone”) and TPG in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3 billion.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021765122/en/ Under the terms of the agreement, Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash plus a non-tradable contingent value right (C
Axelera Announces Europa AIPU, Setting New Industry Benchmark for AI Accelerator Performance, Power Efficiency and Affordability21.10.2025 14:00:00 CEST | Press release
Delivers 629 TOPs processing power for multi-modal AI applications from the edge to the data center Axelera AI, the leading provider of purpose-built AI hardware acceleration technology, today announced Europa™, an AI processor unit (AIPU) that sets a new performance/price standard for multi-user generative AI and computer vision applications. Europa’s combination of processing power, energy and thermal efficiency, compact packaging, and multiple form factor options make it ideal for compute-intensive, multi-modal AI inference applications from the edge to enterprise servers. Designed to be cost effective and accessible, Europa enables any organization to unlock the power of cutting-edge AI applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021493990/en/ Europa™ AIPU Next Gen Architecture for Real World AI Processing Power The Europa AIPU features eight second-generation AI cores, each incorporating Axelera’s ad
Enedym Inc. Secures Investment from Honda Motor Co., Ltd.21.10.2025 14:00:00 CEST | Press release
Enedym’s next generation switched reluctance motor (SRM) drive technology requires no permanent magnets or rare earth metals Enedym Inc. (“Enedym”), a technology company thatdevelops next generation switched reluctance motors (SRMs), electric powertrains, and powertrain controls, announced today an investment from Honda Motor Co., Ltd. (“Honda”). Honda invests in innovative startups through its global open innovation program, Honda Xcelerator Ventures. The new investment will be used to accelerate Enedym’s patented motor technology development and ramp up its operations. Enedym is headquartered at the McMaster Innovation Park in Hamilton, Ontario, Canada. Enedym has ownership of over 70 patents and pending patent applications and related inventions developed by the Canada Excellence Research Chair Laureate Dr. Ali Emadi and his research group at the McMaster Automotive Resource Centre (MARC), McMaster University. The Company is focused on the development of electric motors completely f
ExaGrid Named Finalist for the MSP Channel Awards 202521.10.2025 14:00:00 CEST | Press release
ExaGrid Nominated in 7 Categories for Inaugural Industry Awards ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it has been nominated in six categories for the 1st annual MSP Channel Awards, which celebrates innovation across the IT Channel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021571422/en/ The new MSP Channel Awards build on the legacy of the former SDC Awards to better reflect today's fast-moving IT landscape. As managed services reshape how technology is delivered – from digital transformation and cybersecurity to cloud, data, and automation – these awards recognize the companies, partnerships, and individuals making a real impact across the channel. Voting to determine the winner in each category i
Carevance platform expands access to GE HealthCare’s clinical excellence with advanced patient monitoring and new perioperative hypotension management capability21.10.2025 14:00:00 CEST | Press release
Built on GE HealthCare’s 50+ years of clinical excellence in patient monitoring, Carevance is an advanced, reliable monitoring solution that leverages proprietary algorithms and proven technologies to help hospitals and clinicians deliver consistent, high-quality care. Designed for today’s clinical realities, Carevance helps support clinicians across acute care areas through an enhanced intra-hospital transport workflow and real-time patient data. As part of its capabilities, Carevance introduces the new Cardiac Output Insights feature available directly on the device to support caregivers in managing hemodynamic instability for perioperative care and help enable timely clinical interventions. Hemodynamic instability or hypotension is a common concern for care teams to manage during and after surgery, and can be associated with longer hospital stays and serious postoperative complications, such as organ failure and mortality.i,ii GE HealthCare (Nasdaq: GEHC) today announced it has rece
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom